Chugai Company Description
Chugai Pharmaceutical develops therapies for bone metabolism and blood disorders, cancer, infectious diseases, immune system disorders, and cardiovascular, kidney, and brain diseases. Products include Neutrogin, which treats white blood cell loss related to chemotherapy; Epogin, which treats red blood cell loss caused by chronic kidney failure; Sigmart, an antianginal agent; and Alfarol for osteoporosis. Chugai Pharmaceuticals has foreign operations in Asia, Europe, and North America through subsidiaries and branch locations. Swiss drugs group Roche owns about 60% of Chugai Pharmaceutical.
View the Comprehensive Company Description for Chugai
The Company Description provides a historical perspective of Chugai's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Chugai's evolution in the marketplace.
